Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Shionogi acquires JT Group's pharmaceutical business

Shionogi's acquisition of JT Group's pharmaceutical business. Photo shows, from left, Koji Shimayoshi , Executive Vice President and Representative Director of JT, Isao Teshirogi, Chairman, President and CEO of Shionogi, and Nobumasa Kondo, President and Representative Director of Torii Pharmaceuticals.=May 7,2025,Tokyo

E

Shionogi acquires JT Group's pharmaceutical business

Shionogi's acquisition of JT Group's pharmaceutical business. Photo shows, from left, Koji Shimayoshi , Executive Vice President and Representative Director of JT, Isao Teshirogi, Chairman, President and CEO of Shionogi, and Nobumasa Kondo, President and Representative Director of Torii Pharmaceuticals.=May 7,2025,Tokyo

E

Shionogi acquires JT Group's pharmaceutical business

Shionogi's acquisition of JT Group's pharmaceutical business. Photo shows Isao Teshirogi, Chairman, President and CEO of Shionogi.=May 7,2025,Tokyo

E

Shionogi acquires JT Group's pharmaceutical business

Shionogi's acquisition of JT Group's pharmaceutical business. Photo shows, from left, Koji Shimayoshi , Executive Vice President and Representative Director of JT, Isao Teshirogi, Chairman, President and CEO of Shionogi, and Nobumasa Kondo, President and Representative Director of Torii Pharmaceuticals.=May 7,2025,Tokyo

E

Shionogi to buy U.S. pharmaceutical firm Sciele Pharma

TOKYO, Japan - Isao Teshirogi (R), president of Japanese drug manufacturer Shionogi & Co., poses with Patrick Fourteau, chief executive of Sciele Pharma Inc., at a news conference in Tokyo on Sept. 1, in which Shionogi announced that it will launch a $1.1 billion friendly offer for shares in the Atlanta-based U.S. pharmaceutical company in order to establish a sales base in the United States.

E

Japanese drugmaker Shionogi's president

Isao Teshirogi (C), president of Japanese pharmaceutical firm Shionogi & Co., attends a press conference in Tokyo on March 4, 2022, over the company's COVID-19 vaccine under development.

E

Japanese drugmaker Shionogi's president

Isao Teshirogi, president of Japanese pharmaceutical firm Shionogi & Co., attends a press conference in Tokyo on March 4, 2022, over the company's COVID-19 vaccine under development.

E

Japanese drugmaker Shionogi

The headquarters building of Japanese drugmaker Shionogi & Co. is pictured in Osaka on Dec. 27, 2021.

E

Shionogi's new mid-term management plan briefing

On the 1st, Shionogi announced a new mid-term management plan to invest 500 billion yen in expanding overseas business and launching new businesses by FY2024. The company will also increase research and development expenses by 20% over the past five years to about 342.1 billion yen. In addition to strengthening its own sales of pharmaceuticals in Japan and overseas, the company will also invest heavily in products and services other than ethical drugs, such as vaccines.In terms of sales strategy, the company plans to strengthen its sales in the U.S. and China, and increase the ratio of overseas sales to more than 50% in FY2012 (18.5% in FY2007). President Tedairogi said, "We aim to become a drug discovery company that people from outside the company want to work with," and also indicated that the company will place importance on alliance strategies. (Photo taken on June 1, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)

E

Eli Lilly Japan's logo

Keywords: Eli Lilly Japan, Lilly, pharmaceutical, insulin, Shionogi, company, sign, logo, logo mark = October 25, 2019, headquarters in Kobe, Hyogo Prefecture, credit: Nikkan Kogyo Shimbun / Kyodo News Images

E

Shionogi to buy U.S. pharmaceutical firm Sciele Pharma

TOKYO, Japan - Isao Teshirogi (R), president of Japanese drug manufacturer Shionogi & Co., poses with Patrick Fourteau, chief executive of Sciele Pharma Inc., at a news conference in Tokyo on Sept. 1, in which Shionogi announced that it will launch a $1.1 billion friendly offer for shares in the Atlanta-based U.S. pharmaceutical company in order to establish a sales base in the United States. (Kyodo)

E

Drugmaker Shionogi testing coronavirus vaccine candidate

Isao Teshirogi, president of Japanese pharmaceutical maker Shionogi & Co., gives an interview in Osaka on Dec. 16, 2020. Shionogi has conducted clinical testing for its coronavirus vaccine candidate.

E

Drugmaker Shionogi testing coronavirus vaccine candidate

Isao Teshirogi, president of Japanese pharmaceutical maker Shionogi & Co., gives an interview in Osaka on Dec. 16, 2020. Shionogi has conducted clinical testing for its coronavirus vaccine candidate.

E

Drugmaker Shionogi testing coronavirus vaccine candidate

Isao Teshirogi, president of Japanese pharmaceutical maker Shionogi & Co., gives an interview in Osaka on Dec. 16, 2020. Shionogi has conducted clinical testing for its coronavirus vaccine candidate.